IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

Figure 2

(a) Association of the anti-GlcNAcβ IgG level with the stages of fibrosis in patients infected with HCV-1b (cut-off 0.334). -axis: Ab level values ( minus ). The lower boundary of the box indicates the 25^th percentile data, a line within the box marks the median (), and the upper boundary of the box indicates the 75^th percentile. The bars below and above the box indicate the 10^th and 90^th percentiles, respectively. (b) Association of the anti-GlcNAcβ IgG level with portal inflammation scores. Light boxes symbolize patients infected with HCV-1b and 3a genotypes in stages F0–2 (cut-off 0.248), and dark boxes denote those in stages F0–4 (cut-off 0.248). (c) Association of the pretreatment level of anti-GA2 IgG with the response to antiviral treatment: SVR—patients with sustained viral response ( 0.126); no SVR—patients with nonresponse and relapse ( 0.385), cut-off 0.232.

(a)

(b)

(c)